AMAG Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AMAG)

$13.75 -0.35 (-2.48 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$14.10
Today's Range$13.55 - $14.30
52-Week Range$11.93 - $36.83
Volume928,572 shs
Average Volume1.12 million shs
Market Capitalization$485.22 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86

About AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals logoAMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: Biotechnology
  • Sector: Healthcare
  • Symbol: NASDAQ:AMAG
  • CUSIP: 00163U10
  • Web: www.amagpharma.com
Debt:
  • Debt-to-Equity Ratio: 0.94%
  • Current Ratio: 1.59%
  • Quick Ratio: 1.48%
Sales & Book Value:
  • Annual Sales: $532.09 million
  • Price / Sales: 0.91
  • Cash Flow: $3.16 per share
  • Price / Cash: 4.35
  • Book Value: $27.31 per share
  • Price / Book: 0.50
Profitability:
  • Trailing EPS: ($6.08)
  • Net Income: $-2,480,000.00
  • Net Margins: -35.35%
  • Return on Equity: -0.64%
  • Return on Assets: -0.25%
Misc:
  • Employees: 545
  • Outstanding Shares: 35,370,000
 

Frequently Asked Questions for AMAG Pharmaceuticals (NASDAQ:AMAG)

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) posted its quarterly earnings data on Tuesday, August, 9th. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.20 by $0.25. The specialty pharmaceutical company earned $127.40 million during the quarter, compared to the consensus estimate of $128.52 million. AMAG Pharmaceuticals had a negative net margin of 35.35% and a negative return on equity of 0.64%. AMAG Pharmaceuticals's quarterly revenue was up 46.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.12 EPS. View AMAG Pharmaceuticals' Earnings History.

Where is AMAG Pharmaceuticals' stock going? Where will AMAG Pharmaceuticals' stock price be in 2017?

14 Wall Street analysts have issued 1 year price objectives for AMAG Pharmaceuticals' stock. Their predictions range from $16.00 to $45.00. On average, they expect AMAG Pharmaceuticals' share price to reach $24.27 in the next year. View Analyst Ratings for AMAG Pharmaceuticals.

What are Wall Street analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "AMAG reported earnings of $1.57 in the third quarter of 2017 as against the Zacks Consensus Estimate of a loss. However, the company missed the same on revenues. AMAG lowered its total revenue guidance for 2017. Furthermore, the termination of the licensing agreement with Takeda for Feraheme in ex-U.S. territories was a major setback for the company. So far this year, AMAG’s shares have underperformed the industry.  Nevertheless, the company  is working towards label expansion of Feraheme, and potential approval and launch of the Makena subcutaneous auto-injector (SQ) AMAG also remains focused on expanding Makena’s label further in a bid to increase its market share." (11/8/2017)
  • 2. Cantor Fitzgerald analysts commented, "AMAG announced the commercial launch of Intrarosa (DHEA vaginal insert) as a treatment for moderate to severe dyspareunia associated with vulvar vaginal atrophy (VVA)." (7/24/2017)
  • 3. Jefferies Group LLC analysts commented, "No surprise vs. pre-announced 4Q16 results on 1/9/17. Another acquisition of women's health product Intrarosa also fails to excite investors (following Rekynda on 1/9/17). Given ongoing concerns, near-term we view limited upside; medium/long-term share price recovery would likely be driven by timely approval/successful launch of Makena 3.0 & strong Intrarosa uptake providing confidence in its commercial potential, which may not be materialized until ~2018." (2/15/2017)

Who are some of AMAG Pharmaceuticals' key competitors?

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the folowing people:

  • Gino Santini, Independent Chairman of the Board (Age 60)
  • William K. Heiden, President, Chief Executive Officer, Director (Age 57)
  • Edward Myles CPA, Chief Financial Officer, Senior Vice President - Finance, Treasurer (Age 45)
  • Nathan McBride, Senior Vice President - Innovation Architects, Chief Information Officer
  • Joseph D. Vittiglio, Senior Vice President - Legal Affairs, Technical Operations and Quality, General Counsel, Secretary (Age 45)
  • Tony Casciano, Senior Vice President of Sales and Marketing - Hematology and Oncology business
  • Paul Williams, Senior Vice President - Sales and Marketing, Women’s Health
  • Elizabeth Bolgiano, Senior Vice President of Human Resources
  • Julie Krop M.D., Chief Medical Officer and Senior Vice President - Clinical Development and Regulatory Affairs (Age 51)
  • Scott T. McMillan Ph.D., Senior Vice President - Quality and Technical Operations

Who owns AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (3.25%), Prudential Financial Inc. (2.06%), Robeco Institutional Asset Management B.V. (1.85%), Russell Investments Group Ltd. (1.83%), Schwab Charles Investment Management Inc. (1.20%) and Tocqueville Asset Management L.P. (0.61%). Company insiders that own AMAG Pharmaceuticals stock include Joseph Vittiglio and Julie Krop. View Institutional Ownership Trends for AMAG Pharmaceuticals.

Who sold AMAG Pharmaceuticals stock? Who is selling AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Dimensional Fund Advisors LP, OxFORD Asset Management LLP, Virginia Retirement Systems ET AL, Canada Pension Plan Investment Board, Cornerstone Capital Management Holdings LLC., Skandinaviska Enskilda Banken AB publ and Systematic Financial Management LP. Company insiders that have sold AMAG Pharmaceuticals company stock in the last year include Joseph Vittiglio and Julie Krop. View Insider Buying and Selling for AMAG Pharmaceuticals.

Who bought AMAG Pharmaceuticals stock? Who is buying AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Prudential Financial Inc., Schwab Charles Investment Management Inc., Robeco Institutional Asset Management B.V., Russell Investments Group Ltd., First Midwest Bank Trust Division, Schroder Investment Management Group and GSA Capital Partners LLP. View Insider Buying and Selling for AMAG Pharmaceuticals.

How do I buy AMAG Pharmaceuticals stock?

Shares of AMAG Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG Pharmaceuticals stock can currently be purchased for approximately $13.75.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $485.22 million and generates $532.09 million in revenue each year. The specialty pharmaceutical company earns $-2,480,000.00 in net income (profit) each year or ($6.08) on an earnings per share basis. AMAG Pharmaceuticals employs 545 workers across the globe.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 Winter St, WALTHAM, MA 02451-1427, United States. The specialty pharmaceutical company can be reached via phone at +1-617-4983300 or via email at [email protected]


MarketBeat Community Rating for AMAG Pharmaceuticals (NASDAQ AMAG)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  511
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for AMAG Pharmaceuticals (NASDAQ:AMAG)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 10 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.14)
Consensus Price Target: $24.27 (76.53% upside)

Consensus Price Target History for AMAG Pharmaceuticals (NASDAQ:AMAG)

Price Target History for AMAG Pharmaceuticals (NASDAQ:AMAG)

Analysts' Ratings History for AMAG Pharmaceuticals (NASDAQ:AMAG)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/5/2017Jefferies Group LLCReiterated RatingBuy$16.00N/AView Rating Details
11/3/2017Morgan StanleyLower Price TargetOverweight$26.00 -> $22.00N/AView Rating Details
10/23/2017Janney Montgomery ScottReiterated RatingHoldN/AView Rating Details
10/23/2017Piper Jaffray CompaniesInitiated CoverageNeutral -> Neutral$18.00N/AView Rating Details
9/28/2017Cantor FitzgeraldReiterated RatingHold$21.00HighView Rating Details
8/31/2017Deutsche Bank AGReiterated RatingHold$24.00LowView Rating Details
8/10/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
7/7/2017Citigroup Inc.Lower Price TargetHold$24.00LowView Rating Details
6/1/2017Barclays PLCReiterated RatingEqual Weight$25.00 -> $20.00LowView Rating Details
2/2/2017GuggenheimLower Price TargetBuy$42.00 -> $28.00N/AView Rating Details
1/31/2017J P Morgan Chase & CoSet Price TargetHold$24.00N/AView Rating Details
1/11/2017Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
1/10/2017Leerink SwannDowngradeOutperform -> Market Perform$39.00 -> $25.00N/AView Rating Details
1/9/2017Raymond James Financial, Inc.Reiterated RatingMarket Perform -> UnderperformN/AView Rating Details
3/28/2016Robert W. BairdLower Price TargetOutperform$26.00 -> $25.00N/AView Rating Details
3/28/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralN/AView Rating Details
1/28/2016Northland SecuritiesInitiated CoverageOutperform$40.00N/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for AMAG Pharmaceuticals (NASDAQ:AMAG)

Earnings by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Earnings History by Quarter for AMAG Pharmaceuticals (NASDAQ AMAG)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.58)($0.40)$158.83 million$158.39 millionViewListenView Earnings Details
5/2/2017Q1 2017$0.09($1.06)$150.32 million$139.47 millionViewListenView Earnings Details
2/14/2017Q416$0.24($0.31)$155.12 million$151.60 millionViewListenView Earnings Details
11/3/2016Q316$1.50$1.78$141.65 million$143.80 millionViewListenView Earnings Details
8/9/2016Q216$1.20$1.45$128.52 million$127.40 millionViewListenView Earnings Details
5/3/2016Q116$1.11$0.94$124.83 million$117.60 millionViewListenView Earnings Details
2/17/2016Q415$1.16$1.12$120.13 million$108.70 millionViewListenView Earnings Details
11/3/2015Q315$1.21($0.62)$113.88 million$103.50 millionViewListenView Earnings Details
7/23/2015Q215$0.75$1.12$94.05 million$123.90 millionViewListenView Earnings Details
5/5/2015Q115$1.04$1.11$84.66 million$89.50 millionViewListenView Earnings Details
10/30/2014Q314($0.08)$0.06$26.30 million$25.50 millionViewListenView Earnings Details
7/29/2014Q214($0.09)($0.07)$23.40 million$24.80 millionViewListenView Earnings Details
4/24/2014Q1($0.07)($0.33)$22.73 million$20.80 millionViewListenView Earnings Details
2/6/2014Q4($0.10)($0.17)$21.01 million$21.70 millionViewListenView Earnings Details
10/17/2013Q313($0.12)($0.01)$20.37 million$21.60 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.17)($0.09)$18.51 million$19.60 millionViewListenView Earnings Details
4/23/2013Q1 2013($0.20)($0.18)$17.99 million$17.90 millionViewListenView Earnings Details
3/1/2013Q4 2012($0.06)($0.17)$22.54 million$21.14 millionViewN/AView Earnings Details
11/1/2012Q312($0.26)($0.19)$20.43 million$17.70 millionViewN/AView Earnings Details
7/26/2012($0.39)$0.16ViewN/AView Earnings Details
5/1/2012($0.63)($0.58)ViewN/AView Earnings Details
3/5/2012($1.09)($0.87)ViewN/AView Earnings Details
11/4/2011($0.98)($0.78)ViewN/AView Earnings Details
5/3/2011($0.99)($1.05)ViewN/AView Earnings Details
2/25/2011($1.04)($0.94)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)
2017 EPS Consensus Estimate: ($0.90)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.05)($1.05)($1.05)
Q2 20171$0.58$0.58$0.58
Q3 20171($0.36)($0.36)($0.36)
Q4 20171($0.07)($0.07)($0.07)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AMAG Pharmaceuticals (NASDAQ:AMAG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AMAG Pharmaceuticals (NASDAQ AMAG)

Insider Ownership Percentage: 3.80%
Insider Trades by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Insider Trades by Quarter for AMAG Pharmaceuticals (NASDAQ AMAG)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2017Joseph VittiglioSVPSell1,250$16.75$20,937.50View SEC Filing  
7/13/2017Julie KropSVPSell4,938$20.00$98,760.00View SEC Filing  
5/1/2017Julie KropSVPSell1,891$24.45$46,234.95View SEC Filing  
10/20/2016Julie KropSVPSell4,938$24.80$122,462.40View SEC Filing  
11/10/2015John A FallonDirectorBuy3,230$31.20$100,776.00View SEC Filing  
10/1/2015William K HeidenCEOSell2,000$39.69$79,380.00View SEC Filing  
9/1/2015William K HeidenCEOSell2,000$61.19$122,380.00View SEC Filing  
7/15/2015William K HeidenCEOSell20,000$75.00$1,500,000.00View SEC Filing  
6/15/2015Scott A HolmesSVPSell7,580$66.63$505,055.40View SEC Filing  
6/5/2015William K HeidenCEOSell66,875$69.90$4,674,562.50View SEC Filing  
6/4/2015Frank E ThomasCOOSell20,000$69.47$1,389,400.00View SEC Filing  
6/3/2015Scott A HolmesSVPSell22,516$68.88$1,550,902.08View SEC Filing  
1/9/2015Adage Capital Partners Gp LlcMajor ShareholderSell1,250,000$46.49$58,112,500.00View SEC Filing  
1/9/2014Christopher WhiteInsiderSell4,000$22.37$89,480.00View SEC Filing  
1/7/2014Christopher WhiteInsiderSell5,000$23.90$119,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AMAG Pharmaceuticals (NASDAQ AMAG)

Source:
DateHeadline
Palatin Technologies (PTN) Signs Licensing Agreement with Kwangdong Pharmaceutical for Republic of Korea - StreetInsider.comPalatin Technologies (PTN) Signs Licensing Agreement with Kwangdong Pharmaceutical for Republic of Korea - StreetInsider.com
www.streetinsider.com - November 21 at 9:22 PM
AMAG Pharmaceuticals, Inc. (AMAG) Receives Consensus Rating of "Hold" from AnalystsAMAG Pharmaceuticals, Inc. (AMAG) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 13 at 4:16 PM
 Brokerages Expect AMAG Pharmaceuticals, Inc. (AMAG) Will Announce Quarterly Sales of $163.39 Million Brokerages Expect AMAG Pharmaceuticals, Inc. (AMAG) Will Announce Quarterly Sales of $163.39 Million
www.americanbankingnews.com - November 13 at 1:02 PM
AMAG Pharmaceuticals, Inc. (AMAG) Expected to Post Earnings of $0.10 Per ShareAMAG Pharmaceuticals, Inc. (AMAG) Expected to Post Earnings of $0.10 Per Share
www.americanbankingnews.com - November 11 at 3:26 PM
ETFs with exposure to AMAG Pharmaceuticals, Inc. : November 9, 2017ETFs with exposure to AMAG Pharmaceuticals, Inc. : November 9, 2017
finance.yahoo.com - November 9 at 4:52 PM
AMAG Pharmaceuticals to Present at Upcoming Investor Conference - GlobeNewswire (press release)AMAG Pharmaceuticals to Present at Upcoming Investor Conference - GlobeNewswire (press release)
globenewswire.com - November 8 at 8:43 PM
AMAG Pharmaceuticals to Present at Upcoming Investor ConferenceAMAG Pharmaceuticals to Present at Upcoming Investor Conference
finance.yahoo.com - November 8 at 8:43 PM
FY2018 Earnings Estimate for AMAG Pharmaceuticals, Inc. (AMAG) Issued By Cantor FitzgeraldFY2018 Earnings Estimate for AMAG Pharmaceuticals, Inc. (AMAG) Issued By Cantor Fitzgerald
www.americanbankingnews.com - November 8 at 7:52 PM
AMAG Pharmaceuticals, Inc. (AMAG) Forecasted to Post Q4 2017 Earnings of ($0.07) Per ShareAMAG Pharmaceuticals, Inc. (AMAG) Forecasted to Post Q4 2017 Earnings of ($0.07) Per Share
www.americanbankingnews.com - November 8 at 4:36 PM
AMAG Announces Autologous Cord Blood Cells Improve Motor Function in Some Children with Cerebral PalsyAMAG Announces Autologous Cord Blood Cells Improve Motor Function in Some Children with Cerebral Palsy
finance.yahoo.com - November 8 at 3:41 PM
AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
finance.yahoo.com - November 8 at 3:41 PM
Financial Contrast: AMAG Pharmaceuticals (AMAG) and Collegium Pharmaceutical (COLL)Financial Contrast: AMAG Pharmaceuticals (AMAG) and Collegium Pharmaceutical (COLL)
www.americanbankingnews.com - November 8 at 9:31 AM
Tech Company EmpiraMed Boosts Customer Domain Expertise by Hiring 2 Biopharmaceutical Industry VeteransTech Company EmpiraMed Boosts Customer Domain Expertise by Hiring 2 Biopharmaceutical Industry Veterans
www.bizjournals.com - November 6 at 4:32 PM
Valeant has officially given up its $1 billion bet on the ‘female Viagra’Valeant has officially given up its $1 billion bet on the ‘female Viagra’
www.marketwatch.com - November 6 at 4:32 PM
Hypophosphatemia Data From AMAG Phase 3 Trial Presented at the American Society of NephrologyHypophosphatemia Data From AMAG Phase 3 Trial Presented at the American Society of Nephrology
finance.yahoo.com - November 6 at 4:32 PM
Q4 2017 Earnings Forecast for AMAG Pharmaceuticals, Inc. Issued By Leerink Swann (AMAG)Q4 2017 Earnings Forecast for AMAG Pharmaceuticals, Inc. Issued By Leerink Swann (AMAG)
www.americanbankingnews.com - November 6 at 9:49 AM
Stock Traders Purchase Large Volume of AMAG Pharmaceuticals Call Options (AMAG)Stock Traders Purchase Large Volume of AMAG Pharmaceuticals Call Options (AMAG)
www.americanbankingnews.com - November 6 at 2:28 AM
AMAG Pharmaceuticals, Inc. 2017 Q3 - Results - Earnings Call SlidesAMAG Pharmaceuticals, Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 5 at 3:49 PM
Morgan Stanley Lowers AMAG Pharmaceuticals, Inc. (AMAG) Price Target to $22.00Morgan Stanley Lowers AMAG Pharmaceuticals, Inc. (AMAG) Price Target to $22.00
www.americanbankingnews.com - November 5 at 12:16 PM
AMAG Pharmaceuticals, Inc. (AMAG) Receives "Buy" Rating from Jefferies Group LLCAMAG Pharmaceuticals, Inc. (AMAG) Receives "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - November 5 at 8:56 AM
Edited Transcript of AMAG earnings conference call or presentation 2-Nov-17 12:00pm GMTEdited Transcript of AMAG earnings conference call or presentation 2-Nov-17 12:00pm GMT
finance.yahoo.com - November 4 at 5:21 PM
AMAG Pharmas (AMAG) Q3 Earnings Beat, Lowers 17 Outlook - NasdaqAMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook - Nasdaq
www.nasdaq.com - November 3 at 3:49 PM
AMAG Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Highlights - NasdaqAMAG Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Highlights - Nasdaq
www.nasdaq.com - November 2 at 9:11 PM
Notable Thursday Option Activity: ZGNX, AMAG, FNSRNotable Thursday Option Activity: ZGNX, AMAG, FNSR
www.thestreet.com - November 2 at 4:10 PM
BRIEF-Amag Pharmaceuticals Q3 loss per share $4.31BRIEF-Amag Pharmaceuticals Q3 loss per share $4.31
www.reuters.com - November 2 at 4:10 PM
AMAG Pharmaceuticals reports 3Q lossAMAG Pharmaceuticals reports 3Q loss
finance.yahoo.com - November 2 at 4:10 PM
Is AMAG Pharmaceuticals Inc’s (AMAG) Balance Sheet Strong Enough To Weather A Storm?Is AMAG Pharmaceuticals Inc’s (AMAG) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 2 at 4:10 PM
ETFs with exposure to AMAG Pharmaceuticals, Inc. : October 25, 2017ETFs with exposure to AMAG Pharmaceuticals, Inc. : October 25, 2017
finance.yahoo.com - October 25 at 4:45 PM
AMAG Pharmaceuticals, Inc. (AMAG) Scheduled to Post Quarterly Earnings on WednesdayAMAG Pharmaceuticals, Inc. (AMAG) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 6:04 AM
AMAG Pharmaceuticals, Inc. (AMAG) Expected to Announce Quarterly Sales of $167.23 MillionAMAG Pharmaceuticals, Inc. (AMAG) Expected to Announce Quarterly Sales of $167.23 Million
www.americanbankingnews.com - October 24 at 6:36 AM
AMAG Pharmaceuticals, Inc. (AMAG) Rating Reiterated by Janney Montgomery ScottAMAG Pharmaceuticals, Inc. (AMAG) Rating Reiterated by Janney Montgomery Scott
www.americanbankingnews.com - October 23 at 11:58 PM
Technical Insights on Diagnostic Substances Stocks -- Atossa ... - PR Newswire (press release)Technical Insights on Diagnostic Substances Stocks -- Atossa ... - PR Newswire (press release)
www.prnewswire.com - October 23 at 9:57 PM
Global Intravenous (IV) Iron Drugs Market, 2024 - Increasing Trend towards Bundled ReimbursementsGlobal Intravenous (IV) Iron Drugs Market, 2024 - Increasing Trend towards Bundled Reimbursements
www.finanznachrichten.de - October 23 at 4:52 PM
AMAG Pharmaceuticals to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday ... - GlobeNewswire (press release)AMAG Pharmaceuticals to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday ... - GlobeNewswire (press release)
globenewswire.com - October 19 at 9:21 PM
AMAG Pharmaceuticals to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, November 2, 2017 at 8:00 a.m. ETAMAG Pharmaceuticals to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, November 2, 2017 at 8:00 a.m. ET
finance.yahoo.com - October 19 at 4:20 PM
AMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Recommendation of "Hold" by AnalystsAMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - October 19 at 2:52 PM
Global Intravenous (IV) Iron Drugs IndustryGlobal Intravenous (IV) Iron Drugs Industry
finance.yahoo.com - October 18 at 5:04 PM
Head to Head Comparison: Patheon NV (PTHN) and AMAG Pharmaceuticals (AMAG)Head to Head Comparison: Patheon NV (PTHN) and AMAG Pharmaceuticals (AMAG)
www.americanbankingnews.com - October 16 at 4:32 AM
Antares Pharma Provides XYOSTED™ Regulatory Update - GlobeNewswire (press release)Antares Pharma Provides XYOSTED™ Regulatory Update - GlobeNewswire (press release)
globenewswire.com - October 12 at 9:45 PM
Commit To Purchase AMAG Pharmaceuticals At $12, Earn 13.2% Annualized Using Options - TheStreet.comCommit To Purchase AMAG Pharmaceuticals At $12, Earn 13.2% Annualized Using Options - TheStreet.com
www.thestreet.com - October 12 at 4:37 PM
ETFs with exposure to AMAG Pharmaceuticals, Inc. : October 11, 2017ETFs with exposure to AMAG Pharmaceuticals, Inc. : October 11, 2017
finance.yahoo.com - October 11 at 5:20 PM
AMAG Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMAG) : October 11, 2017AMAG Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMAG) : October 11, 2017
finance.yahoo.com - October 11 at 5:20 PM
AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : October 10, 2017AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : October 10, 2017
finance.yahoo.com - October 10 at 5:13 PM
AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : October 10, 2017AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : October 10, 2017
finance.yahoo.com - October 10 at 5:13 PM
PacBio And Bluebee Launch De Novo Genome Assembly Pipeline On The Bluebee Analysis PlatformPacBio And Bluebee Launch De Novo Genome Assembly Pipeline On The Bluebee Analysis Platform
www.thestreet.com - October 9 at 4:48 PM
Zacks Investment Research Upgrades AMAG Pharmaceuticals, Inc. (AMAG) to BuyZacks Investment Research Upgrades AMAG Pharmaceuticals, Inc. (AMAG) to Buy
www.americanbankingnews.com - October 8 at 7:56 PM
$1.25 EPS Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter$1.25 EPS Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter
www.americanbankingnews.com - October 3 at 8:14 PM
ETFs with exposure to AMAG Pharmaceuticals, Inc. : September 29, 2017ETFs with exposure to AMAG Pharmaceuticals, Inc. : September 29, 2017
finance.yahoo.com - October 2 at 3:38 PM
AMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance Officer - GlobeNewswire (press release)AMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance Officer - GlobeNewswire (press release)
globenewswire.com - September 29 at 8:18 PM
AMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance OfficerAMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance Officer
feeds.benzinga.com - September 29 at 8:20 AM

Social Media

Financials

Chart

AMAG Pharmaceuticals (NASDAQ AMAG) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.